- In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Antimicrobial agents and chemotherapy (2007-06-27)
Cédric Jacqueline, Jocelyne Caillon, Virginie Le Mabecque, Anne-Françoise Miègeville, Antoine Hamel, Denis Bugnon, James Yigong Ge, Gilles Potel
PMID17591849
ABSTRACT
Using the rabbit endocarditis model, we compared the activity of a new broad-spectrum cephalosporin, ceftaroline, with those of linezolid and vancomycin against methicillin-resistant Staphylococcus aureus. After a 4-day treatment, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S. aureus strain.
MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto